KP-1461 id a viral decay acceleration agent, inducing mutations within the HIV genome leading to degraded viral fitness and viral collapse. This is contrast to most HIV treatments which are designed to inhibit growth, according to Robert Schooley, lead principal investigator for the trial.
“While KP-1461 has demonstrated the potential to ablate HIV infection in vitro and was generally safe and well tolerated in phase I trials, this phase 2a trial will provide the first opportunity to evaluate the efficacy of the VDA approach in HIV infected patients,” said Stephen Becker, chief medical officer of Koronis. “We eagerly await the results of this trial and the potential future development opportunities of the drug.”
The trial will evaluate the safety, efficacy and tolerability when KP-1461 is administered as monotherapy in treatment-experienced patients. Up to 32 individuals who harbor significant resistance to conventional antiretroviral therapies will be enrolled, and will receive 1600mg of KP-1461 twice daily for 124 days.